Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $425.0 million
Deal Type : Acquisition
Calypso Enters into Agreement to be Acquired by Novartis
Details : Novartis acquires CALY-002, a therapeutic antibody targeting Interleukin-15 for dermatology, gastrointestinal, and rheumatology applications.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $250.0 million
August 01, 2024
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $425.0 million
Deal Type : Acquisition
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. The study is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
